SN38 Recombinant Monoclonal Antibody

SN38, also known as 7-ethyl-10-hydroxycamptothecin, is the active metabolite of irinotecan and represents a critical compound in cancer research and therapeutic development. As a potent topoisomerase I inhibitor, SN38 demonstrates significantly greater cytotoxic activity than its parent compound and serves as the cytotoxic payload in several antibody-drug conjugates currently under clinical investigation. Reliable detection of this small molecule is essential for pharmacokinetic studies, drug conjugate characterization, and therapeutic monitoring applications.

This recombinant monoclonal antibody, clone 10G11D5, was generated against SN38-BSA conjugate and provides researchers with a sequence-defined detection tool that eliminates the lot-to-lot variability inherent in traditional hybridoma-derived antibodies. The IgG2a isotype antibody has been affinity-purified to ensure high specificity, and its recombinant production guarantees consistent performance across extended research programs where reproducibility is paramount.

Validation studies demonstrate excellent binding activity in ELISA applications, with the antibody successfully detecting Labetuzumab govitecan, an SN38-conjugated antibody therapeutic. Functional ELISA testing showed robust binding with EC50 values ranging from 3.326 to 4.721 ng/mL when Labetuzumab govitecan was immobilized at 2 μg/mL, confirming the antibody's sensitivity for detecting SN38 moieties in conjugated formats. Recommended working dilutions span 1:5000 to 1:50000, offering flexibility to optimize signal-to-noise ratios across different experimental conditions.

This antibody serves researchers investigating antibody-drug conjugate development, SN38 pharmacokinetics, and topoisomerase-targeted cancer therapeutics, providing a dependable tool for quantitative detection of this clinically significant compound.